Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients

AIDS Research and Human Retroviruses

Volumn 23, Issue 7, 2007, Pages 863-867

  Castro, Pedro ^a   Laguno, Montserrat ^a   Nomdedeu, Meritxell ^a   López, Anna ^a   Plana, Montserrat ^a   Fumero, Emilio ^a   Gallart, Teresa ^a   Mallolas, Josep ^a   Gatell, José M ^a   García, Felipe ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; LIVER ENZYME;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOMEGALY; HIV INFECTIONS; HIV-1; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34547949156     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0251     Document Type: Article

References (19)

1. Koziel MJ: Influence of HIV co-infection on hepatitis C immunopathogenesis. J Hepatol 2006;44(Suppl.):S14-18.
2. Verucchi G, Calza L, Manfredi R, and Chiodo F: Human immunodeficiency virus and hepatitis C virus coinfection: Epidemiology, natural history, therapeutic options and clinical management. Infection 2004;32:33-46.
3. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, et al.: Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004;40:125-132.
4. Alatrakchi N, Graham CS, He Q, Sherman KE, and Koziel MJ: CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis 2005;191:702-709.
5. Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al.: Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 2005;19:767-773.
6. Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al.: Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 2006;20:345-351.
7. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, et al.: Care of patients with hepatitis C and HIV co-infection. AIDS 2004;18:1-12.
8. Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, and Gazzard B: Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005;41:906-911.
9. Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO, et al.: Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;39:613-619.
10. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al.: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002.
11. Alatrakchi N, Di M, V, Thibault V, Benhamou Y, Katlama C, Poynard T, et al.: Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. AIDS 2004;18:121-123.
12. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, and Demarest JF: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332:209-217.
13. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
14. Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, Lederman MM, et al.: HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS. 2002;16:1113-1118.
15. Alatrakchi N, Di M, V, Thibault V, and Autran B: Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 2002; 16:713-717.
16. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-F36.
17. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al.: Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.
18. Bacon BR: Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36:S179-S184.
19. Torriani F, Rodriguez-Torres M, Lissen E, Brau N, Sola R, Clotet B, Clumeck N, Cooper D, and Dieterich DT: Predictability of virologic response at week 4 and 12 of peginterferon alfa-2a (40KD) plus ribavirin (RBV) therapy in HIV-HCV co-infection: AIDS PEGASYS Ribavirin International Co-Infection Trial (APRICOT) Abstract V-1178. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, December, 16-19, 2005.